Literature DB >> 8689207

Antegrade colonic enemas.

A C Dick1, W A McCallion, S Brown, V E Boston.   

Abstract

Thirteen children aged 6-14 (mean 8) years in whom an antegrade colonic enema procedure was performed were reviewed retrospectively. All presented with refractory constipation or faecal soiling over a 3-year period. Nine of the children had previously undergone pull-through procedures for Hirschsprung's disease or high anorectal malformations. Two were suffering from spina bifida and two from idiopathic functional constipation. The operation was performed through a right iliac fossa incision. A catheterizable conduit was created. The appendix was brought out to the wound edge and made continent by intussuscepting the appendix base into the caecum. When the appendix was absent or unusable, a caecal tube was formed. Five patients suffered minor morbidity, six required a further operative procedure and two eventually required a sigmoid colostomy. However, the eventual outcome of a continent stoma was attained in 11 of the 13 children, all of whom would have been considered for sigmoid colostomy before introduction of the antegrade colonic enema procedure.

Entities:  

Mesh:

Year:  1996        PMID: 8689207     DOI: 10.1002/bjs.1800830517

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  3 in total

1.  Treatment of a leaking ACE conduit with Deflux injections.

Authors:  A Koivusalo; M P Pakarinen; R J Rintala
Journal:  Pediatr Surg Int       Date:  2006-12       Impact factor: 1.827

2.  Successful pregnancy and delivery following a Malone antegrade continence enema procedure.

Authors:  M C Macdonald; J P Garner; K F Selby; R Nelson
Journal:  Tech Coloproctol       Date:  2009-07-15       Impact factor: 3.781

3.  Malone antegrade continence enema (MACE) for fecal incontinence in imperforate anus improves quality of life.

Authors:  Kelly D Mattix; Nathan M Novotny; Anita A Shelley; Frederick J Rescorla
Journal:  Pediatr Surg Int       Date:  2007-12       Impact factor: 1.827

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.